Key clinical point: Talazoparib did not confer an overall survival benefit over chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer.
Major finding: The median overall survival was 19.3 months in the talazoparib arm and 19.5 months in the chemotherapy arm (hazard ratio, 0.848, P = .17)
Study details: Final survival analysis of the phase 3 EMBRACA study of 431 patients.
Disclosures: The EMBRACA trial was funded by Medivation (Pfizer). The researchers disclosed numerous relationships with pharmaceutical companies and other organizations.
Litton J et al. AACR 2020, Abstract CT0071.